Agenda Strawman – DAY 1

7:30-8:15 a.m.  Breakfast

8:30-8:45 a.m.  Welcome
     Peter Davies
     Diana Kerwin

8:45-8:50 a.m.  First Plenary Introduction
     Luc Buee

8:50-9:20 a.m.  First Plenary
     Tau Research: History and Current Status
     Jean-Pierre Brion

Session 1:  Tauopathies

9:20-9:40 a.m.  Tau in Frontotemporal Dementias
     Maria Spillantini

9:40-10 a.m.  NPC/Other Secondary Tauopathies
     Marc Patterson

10:20-10:45 a.m.  Break

Session 2:  Tau Imaging

10:45-11:05 a.m.  Overview of Tau Imaging
     Keith Johnson

11:05-11:25 a.m.  Tau Imaging in Non AD Tauopathies
     Gil Rabinovici

11:25-11:45 a.m.  Taupography: What Does It Tell Us?
     Gael Chetelat

11:45 a.m.-12:05 p.m.  Biomarker Lead for Semorinemab and \([^{18}\text{F}]\)GTP1 at Genentech
     Kristin Wildsmith

12:05-12:30 p.m.  Panel Discussion
     Moderator: Margaret Sutherland

12:30-1:45 p.m.  Lunch and Poster Viewing

1:45-2:45 p.m.  Lightning Poster Session
     Moderator: Luc Buee

2:45-2:50 p.m.  Second Plenary Introduction
     Kathryn Bowles
Second Plenary
What Genetic and Functional Studies Have Taught Us About the Role of MAPT in Neurodegeneration?
Alison Goate

Session 3: Genetics and Tauopathies
3:20-3:40 p.m. Molecular Drivers of Primary Tauopathy
Celeste Karch
3:40-4:05 p.m. Common Genetic Features in Primary Tauopathies
John Hardy & Huw Morris
4:05-4:25 p.m. Imaging and Cognitive Profile of Colombian Families With Tauopathies
Yakeel Quiroz

Panel Discussion and Keynote
Moderator: Martin Citron

Break

Open AD: Open Science and Drug Discovery
Aled Edwards

Panel and Debate
Moderator: Samantha Budd
Propagation vs. Selective Vulnerability
Marc Diamond
Bess Frost
vs.
Karen Duff
Brad Hyman

Lightning Rounds for CUREPSP
Moderator: Larry Golbe

Close of Day One
Maria Carrillo

Agenda Strawman – DAY 2
7:30-8:30 a.m. Breakfast
### Tau 2020
February 12-13, 2020 | Washington, D.C.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-8:45 a.m.</td>
<td>Open of Day Two</td>
<td>Maria Carrillo</td>
</tr>
<tr>
<td><strong>Session 4:</strong></td>
<td><strong>Molecular Mechanism for Therapeutic Approaches</strong></td>
<td></td>
</tr>
<tr>
<td>8:45-9:05 a.m.</td>
<td>Exploring Tau Between and Within Cells</td>
<td>Kenneth S. Kosik</td>
</tr>
<tr>
<td>9:05-9:25 a.m.</td>
<td>Exploring the Biodistribution of Tau-Targeting BBB-Penetrant Fusion Proteins in the CNS</td>
<td>Sarah DeVos</td>
</tr>
<tr>
<td>9:25-9:45 a.m.</td>
<td>Progress and Challenges Advancing the National Plan to Address AD/ADRD</td>
<td>Eliezer Masliah</td>
</tr>
<tr>
<td>9:45-10:05 a.m.</td>
<td>PROTAC</td>
<td>Angela Cacace</td>
</tr>
<tr>
<td>10:05-10:25 a.m.</td>
<td>Panel Discussion</td>
<td>Mike Hutton</td>
</tr>
<tr>
<td>10:25-10:50 a.m.</td>
<td>Break and Checkout</td>
<td></td>
</tr>
<tr>
<td>10:50-11:50 a.m.</td>
<td>Rainwater Prize Ceremony and Winners’ Keynotes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tau Therapeutics: Translational Challenges in Moving From Bench to Bedside</td>
<td></td>
</tr>
<tr>
<td>11:50 a.m.-</td>
<td>Second Lightning Poster Session</td>
<td></td>
</tr>
<tr>
<td>12:50 p.m.</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12:50-2 p.m.</td>
<td></td>
<td>Diana Kerwin</td>
</tr>
<tr>
<td>2:05-2:35 p.m.</td>
<td>Third Plenary</td>
<td></td>
</tr>
<tr>
<td>2:05-2:35 p.m.</td>
<td>Tau Therapeutics: Translational Challenges in Moving From Bench to Bedside</td>
<td>Adam Boxer</td>
</tr>
<tr>
<td><strong>Session 5:</strong></td>
<td><strong>Tau Therapeutics</strong></td>
<td></td>
</tr>
<tr>
<td>2:35-2:55 p.m.</td>
<td>Initial Results From a Phase 2 Study of the Pan-Tau Antibody 8E12 in Patients With Progressive Supranuclear Palsy</td>
<td>Mike Gold</td>
</tr>
<tr>
<td>2:55-3:15 p.m.</td>
<td>ASOs</td>
<td>Tim Miller</td>
</tr>
<tr>
<td>3:15-3:35 p.m.</td>
<td>Clinical Overview of Tau Targets</td>
<td>Cath Mummery</td>
</tr>
<tr>
<td>3:35-3:55 p.m.</td>
<td>Industry Overview of Tau Targets</td>
<td>Philipp von Rosentiel</td>
</tr>
</tbody>
</table>
Panel Discussion
Moderator: Howard Feldman

Break

Panel Session
Early Stage Investment in Tau Therapeutics
Moderators: Pat Brannelly
Stacie Weninger (FBRI)
James Mutamba (Longwood Fund)
Dirk Beher (Asceneuron)

Closing Remarks